NEW YORK (GenomeWeb) – Expedeon said today it has signed a supply and license agreement with Quanterix to provide that company non-exclusive access to its immunoassay offerings.
Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.
Financial and other terms of the agreement were not disclosed.
The CaptSure immunoassay system uses a universal base for immobilizing antibodies, which the company said can be combined with the Lightning-Link system to more quickly develop and deploy immunoassays on different test platforms.
"Combining our technologies with those of Quanterix will provide the industry with unmatched new capabilities for protein discovery," Heikki Lanckreit, Expedeon's CEO and CSO said in a statement. "We are extremely excited about this new venture and look forward to examining further opportunities with Quanterix as the partnership expands."
“We are pleased to be able to incorporate Expedeon technologies in our newest product offerings, providing additional flexibility and performance to researchers utilizing our Simoa technology to measure digital biomarkers and fuel new discoveries,” said Kevin Hrusovsky, CEO, president and chair of Quanterix.